ADVERTISEMENT
2 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Forest Licenses A Microbia Drug

September 24, 2007 | APPEARED IN VOLUME 85, ISSUE 39

Forest Laboratories will pay up to $330 million for access to linaclotide, a first-in-class compound being developed by Microbia for the treatment of irritable bowel syndrome. Linaclotide activates the guanylate cyclase type-C receptor, a protein found in the lining of the intestines that increases fluid secretion. Forest and Microbia will jointly fund development and commercialization in the U.S., and Microbia will retain rights outside North America. Linaclotide is currently in Phase IIb studies and is expected to progress into Phase III in the second half of next year.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment